RT Journal Article
T1 Update of the SEPD position statement on the use of biosimilars for inflammatory bowel disease.
A1 Argüelles Arias, Federico
A1 Hinojosa Del Val, Joaquín
A1 Vera Mendoza, Isabel
AB In 2013, the European Medicines Agency (EMA) approved the biosimilar infliximab (CT-P13) for the full range of indications of the originator product, based on data from two trials conducted in rheumatoid arthritis and ankylosing spondylitis. The same year, our Society published a position statement that was later reviewed.
SN 1130-0108
YR 2018
FD 2018
LK http://hdl.handle.net/10668/12230
UL http://hdl.handle.net/10668/12230
LA en
DS RISalud
RD Jul 4, 2025